LOW-VOLUME · SEX-BALANCED
netarsudil Side Effects
netarsudil (also sold as Rhopressa) is a LOW-VOLUME FAERS extract #466 of 524 by FAERS report count. Still opens on SEX-BALANCED: 61% of sex-coded reports are female (805 F / 511 M).
Data updated 2026-05-15
- 1,797
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
netarsudil reporting skew - 61% of sex-coded reports are female (805 F / 511 M). Volume band LOW-VOLUME #466 of 524 by FAERS report count; caseload SIGNAL.
Thinner FAERS extract for netarsudil (Rhopressa) (1,797 reports #466 of 524 by FAERS report count). 61% of sex-coded reports are female (805 F / 511 M). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2017–2025). Stamps SIGNAL · DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED.
CONJUNCTIVAL HYPERAEMIA leads 244 of 1,797 reports
Who reports · age peak 75+ (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 75+ (326 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 56 reports (3.1% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 49 |
| ACUTE MYELOID LEUKAEMIA | 3 |
| ACUTE RESPIRATORY FAILURE | 1 |
| AGITATION | 1 |
| ARTERIOSCLEROSIS | 1 |
| BLOOD CHLORIDE DECREASED | 1 |
| BLOOD CREATININE DECREASED | 1 |
| BLOOD GLUCOSE DECREASED | 1 |
| BLOOD POTASSIUM DECREASED | 1 |
| BLOOD SODIUM DECREASED | 1 |
| BODY HEIGHT DECREASED | 1 |
| CARDIAC FAILURE CONGESTIVE | 1 |
| CYTOKINE RELEASE SYNDROME | 1 |
| DEMENTIA | 1 |
| DYSPNOEA | 1 |
| FALL | 1 |
| FATIGUE | 1 |
| HALLUCINATION | 1 |
| HYPOTENSION | 1 |
| HYPOXIA | 1 |
Reactions in Hospitalization Reports
Hospitalization is lighter here (97). Reactions in that subset:
| Reaction | Reports |
|---|---|
| PLEURAL EFFUSION | 10 |
| FATIGUE | 8 |
| FALL | 7 |
| GENERALISED OEDEMA | 7 |
| NAUSEA | 6 |
| CARDIAC FAILURE CONGESTIVE | 5 |
| DEATH | 5 |
| DIARRHOEA | 5 |
| CEREBROVASCULAR ACCIDENT | 4 |
| CONSTIPATION | 4 |
| DYSPNOEA | 4 |
| HAEMOGLOBIN DECREASED | 4 |
| THERAPY INTERRUPTED | 4 |
| VISUAL IMPAIRMENT | 4 |
| WEIGHT DECREASED | 4 |
| ANXIETY | 3 |
| ARTHRALGIA | 3 |
| ASTHENIA | 3 |
| BLOOD GLUCOSE DECREASED | 3 |
How to read netarsudil FAERS figures (SIGNAL · DEATH-MARKED · HOSP-LIGHT)
FAERS holds 1,797 voluntary reports linked to netarsudil (Rhopressa), 2017-2025. Death is listed on 56 (3.1%). Hospitalization appears on 97 (5.4%). Top co-reported indication: Glaucoma.
Sparse extract - named reactions and SEX-BALANCED skew still differ by drug; not a complete safety profile.
Read with netarsudil
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-LIGHT stamps.
ABS(total_reports) peer at 1,829 FAERS cases (Δ 32 heavier vs netarsudil); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED.
ABS(total_reports) peer at 1,831 FAERS cases (Δ 34 heavier vs netarsudil); DEATH-MARKED · HOSP-MID · FEMALE-LED vs this page's SIGNAL · DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED.
ABS(total_reports) peer at 1,858 FAERS cases (Δ 61 heavier vs netarsudil); DEATH-HEAVY · HOSP-MID · FEMALE-LED vs this page's SIGNAL · DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED.
ABS(total_reports) peer at 1,714 FAERS cases (Δ 83 lighter vs netarsudil); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 59.0 pp vs netarsudil's DEATH-MARKED): CASELOAD · HOSP-MID.
netarsudil stamps SIGNAL · SEX-BALANCED; class peers and methodology beat restating the same FAERS caveats on every effects URL.